Supernus Q4 revenue $211.6M (+21% YoY), FY revenue $719M (+9%); FY26 guidance $840-870M

SUPERNUS PHARMACEUTICALS, INC.

2025-FY EPS reported -$0.68 revenue$718,952,000

Record Q4 total revenue $211.6M (+21% YoY); full year $719.0M (+9% YoY).
Growth products (Qelbree, GOCOVRI, ZURZUVAE, ONAPGO) combined revenue $161.3M in Q4 (+45% YoY).
ONAPGO net sales $8.9M since launch; new patient initiation resumed Q1 2026; second supplier expected 2027.
Cash and marketable securities $308.7M at Dec 31, 2025.
FY 2026 guidance: revenue $840-870M, operating earnings $0-30M, adjusted operating earnings $140-170M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.